Review
Oncology
Satya Das, Sharon Phillips, Cody L. Lee, Rajiv Agarwal, Emily Bergsland, Jonathan Strosberg, Jennifer A. Chan, Heather LaFerriere, Robert A. Ramirez, Jordan Berlin, Arvind Dasari
Summary: This study aimed to compare the efficacy and toxicity of anti-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (RTKIs) in patients with neuroendocrine tumors (NETs). The results showed that anti-VEGF RTKIs demonstrated anti-tumor effects in both pancreatic NETs and extra-pancreatic NETs and were safe and reliable in patients.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Pharmacology & Pharmacy
Yusuke Masuo, Ken-ichi Fujita, Kazuhiro Shimada, Noriho Iida, Tomohiko Wakayama, Yukio Kato, Aya Hasan Alshammari
Summary: This study explains the occurrence of hand-foot skin reaction (HFSR) in patients treated with tyrosine kinase inhibitors (TKIs) by examining keratinocyte toxicity and VEGFR-2 inhibition.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Urology & Nephrology
Victor Fages, Arnaud Jannin, Mehdi Maanaoui, Francois Glowacki, Christine Do Cao
Summary: We present a case of a 66-year-old woman with thyroid carcinoma who had persistent proteinuria despite maximal angiotensin-converting enzyme inhibitor dose. Treatment with SGLT2 inhibitor Dapagliflozin resulted in a significant reduction in proteinuria after 3 months. This is the first reported case of successful proteinuria reduction with SGLT2i in a patient treated with tyrosine kinase inhibitor.
JOURNAL OF NEPHROLOGY
(2023)
Review
Biochemistry & Molecular Biology
Manali Tilak, Jennifer Holborn, Laura A. New, Jasmin Lalonde, Nina Jones
Summary: Glioblastoma multiforme (GBM) is a deadly cancer with limited response to existing therapies. Subtypes of GBM with distinct genetic signatures show aberrant activation of signal transduction pathways. Current research focuses on understanding these molecular alterations to develop more efficient targeted therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Endocrinology & Metabolism
Zoe A. Efstathiadou, Charalambos Tsentidis, Alexandra Bargiota, Vasiliki Daraki, Kalliopi Kotsa, Georgia Ntali, Labrini Papanastasiou, Stelios Tigas, Konstantinos Toulis, Kalliopi Pazaitou-Panayiotou, Maria Alevizaki
Summary: Treatment with TKIs in patients with advanced MTC provides moderate therapeutic benefit, with 73% of patients achieving disease stability or partial response. The toxicity associated with these drugs is significant but manageable.
EUROPEAN THYROID JOURNAL
(2021)
Review
Oncology
Paula Aldaz, Imanol Arozarena
Summary: Glioblastoma (GBM) is the most common and lethal form of malignant brain tumor, and patients typically undergo surgery followed by radiotherapy and chemotherapy. Despite promising preclinical evidence, clinical trials testing the therapeutic potential of tyrosine kinase inhibitors (TKIs) targeting EGFR, PDGF receptors, and other tyrosine kinases have not led to significant breakthroughs in treating GBM over the past two decades. This article critically analyzes the reasons for the failure of TKIs in GBM treatment and proposes alternative approaches for the evaluation of TKIs in GBM patients.
Review
Oncology
Po-Chun Hsieh, Yao-Kuang Wu, Chun-Yao Huang, Mei-Chen Yang, Chan-Yen Kuo, I-Shiang Tzeng, Chou-Chin Lan
Summary: A meta-analysis was conducted to evaluate the T790M mutation rate after EGFR-TKI treatment, showing that erlotinib and gefitinib had higher rates of T790M mutation compared to afatinib. The T790M mutation rate was significantly lower with afatinib than with gefitinib and erlotinib treatments. T790M mutation plays an important role in determining further treatment and prognosis.
FRONTIERS IN ONCOLOGY
(2022)
Review
Pharmacology & Pharmacy
Kinga Krawczyk, Katarzyna Sladowska, Przemyslaw Holko, Pawel Kawalec
Summary: This study aimed to compare the safety profile of tyrosine kinase inhibitors (TKIs) used as monotherapy or combination therapy for the first-line treatment of metastatic clear cell RCC. The results showed that sorafenib and tivozanib used as monotherapy were the best treatment options, while the safety profile was poorer when TKIs were used in combination with immunological agents.
FRONTIERS IN PHARMACOLOGY
(2023)
Review
Peripheral Vascular Disease
Ferdinand A. C. le Noble, Jean-Jacques Mourad, Bernard I. Levy, Harry A. J. Struijker-Boudier
Summary: Drugs inhibiting VEGF have been widely used in cancer treatment, but they often cause cardiovascular side effects, with hypertension being the most frequently observed. This review explores the mechanism behind VEGF inhibitor-induced hypertension, focusing on microvascular rarefaction, which is supported by evidence from experimental and clinical studies.
Review
Biochemistry & Molecular Biology
Qiyun Shi, Juncheng Xuhong, Hao Tian, Man Qu, Yi Zhang, Jun Jiang, Xiaowei Qi
Summary: This systematic review and meta-analysis study examines the predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with TKIs. The analysis of 17 studies involving 1706 patients shows that wild-type PIK3CA patients had higher complete response rates and objective response rates compared to mutated PIK3CA patients. Additionally, PIK3CA mutations were marginally associated with poorer progression-free survival and overall survival in metastatic breast cancer patients. Therefore, PIK3CA mutations can predict treatment response in HER2-positive breast cancer patients treated with TKI-containing regimens.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2023)
Review
Oncology
Daisy Wai-Ka Chan, Horace Cheuk-Wai Choi, Victor Ho-Fun Lee
Summary: This study conducted a systematic review and meta-analysis to investigate the treatment-related adverse events (trAEs) of combined epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) and immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer (NSCLC). The results demonstrated a higher incidence of grade >= 3 trAEs in combination TKI and ICI, particularly in skin, gastrointestinal tract, and interstitial lung diseases. However, the interpretation of these results should be cautious due to the limited number of studies included in this meta-analysis.
Review
Oncology
Ruihua Duan, Fen Gong, Yan Wang, Caixia Huang, Jiaming Wu, Leihao Hu, Min Liu, Shijun Qiu, Liming Lu, Yisheng Lin
Summary: This meta-analysis suggests that TACE plus TKIs may have benefits for patients with unresectable hepatocellular carcinoma in terms of TTP, OS, and tumor response rates. However, combination therapy is also associated with a significantly increased risk of adverse reactions. Therefore, the clinical benefits and risks of combination therapy must be evaluated.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Zhou Fu, Su Zhang, Xiaoying Gu, Tao Guan, Chengmeng Wang, Jiaqi Zhang, Yun Wang, Hua Guo, Lu Wang, Ti Zhang
Summary: Tyrosine kinase inhibitors (TKIs) can cause severe proteinuria, which affects tumor therapy. Current therapies for proteinuria are not effective for TKI-induced proteinuria. This study found that different types of proteinuria are related to podocyte damage caused by changes in the RelA signaling pathway. Liuwei Dihuang Pill (LDP) was found to attenuate the inflammatory injury of podocytes by inhibiting the activation of RelA, thereby relieving TKI-induced proteinuria and preventing the progression of TMA and FSGS. The findings suggest that LDP may be a clinically significant treatment for TKI-induced proteinuria.
FRONTIERS IN MEDICINE
(2023)
Review
Biochemistry & Molecular Biology
Javier Torres-Jimenez, Victor Albarran-Fernandez, Javier Pozas, Maria San Roman-Gil, Jorge Esteban-Villarrubia, Alfredo Carrato, Adriana Rosero, Enrique Grande, Teresa Alonso-Gordoa, Javier Molina-Cerrillo
Summary: Urothelial carcinoma, one of the most prevalent types of cancer worldwide, is experiencing a paradigm shift in its therapeutic landscape with the development of different therapies. Increased knowledge of the pathogenesis and genetic alterations in urothelial carcinoma is also contributing to this transformation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Editorial Material
Immunology
Pin Li, Napoleone Ferrara
Summary: This study reveals the crosstalk between VEGF receptors in different organs and emphasizes the importance of VEGF receptor expression and interplay in vascular heterogeneity.
JOURNAL OF EXPERIMENTAL MEDICINE
(2022)